Description
Letrozol CRCA Coated Tablets 2.5 mg. №90
Ingredients
Each tablet contains 2.5 mg of Letrozole.
Mechanism of Action
Letrozole, the active ingredient in Letrozol CRCA, is a nonsteroidal aromatase inhibitor. It works by inhibiting the aromatase enzyme, thereby reducing estrogen production in postmenopausal women. This decrease in estrogen levels helps in the treatment of hormone receptor-positive breast cancer.
Pharmacological Properties
Letrozole is a selective inhibitor of aromatase, an enzyme involved in estrogen biosynthesis. By reducing estrogen levels, Letrozole inhibits the growth of hormone-sensitive breast cancer cells. Its pharmacokinetics include rapid absorption with peak plasma concentrations reached within 2 hours after oral administration.
Indications for Use
Letrozol CRCA is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also used for extended adjuvant treatment in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy.
Contraindications
Do not use Letrozol CRCA if you are pregnant, breastfeeding, or allergic to letrozole. It is contraindicated in premenopausal women, individuals with a known hypersensitivity to letrozole, and those with a history of estrogen receptor-positive breast cancer.
Side Effects
Common side effects of Letrozol CRCA may include hot flashes, fatigue, joint pain, osteoporosis, and increased sweating. Serious side effects such as bone fractures and cardiovascular events are rare but may occur. Contact your healthcare provider if you experience any severe or persistent side effects.
Usage Instructions
The recommended dosage of Letrozol CRCA is one 2.5 mg tablet taken orally once daily, with or without food. It is important to take the tablet whole with a glass of water. Follow the instructions of your healthcare provider regarding the duration of treatment.
Benefits Compared to Analogues
Letrozole has demonstrated superior efficacy over tamoxifen in terms of disease-free survival and overall survival rates in postmenopausal women with hormone receptor-positive early breast cancer. Its controlled-release formulation in Letrozol CRCA ensures consistent drug levels for optimal therapeutic outcomes.
Suitable Patient Groups
Letrozol CRCA is specifically formulated for postmenopausal women with hormone receptor-positive breast cancer. It is not recommended for use in premenopausal women or men. Elderly patients may require dose adjustments based on their renal and hepatic function.
Storage and Shelf Life
Store Letrozol CRCA at room temperature away from moisture and heat. Keep the tablets in the original package to protect them from light. Check the expiration date on the packaging and do not use the tablets beyond the stated shelf life.
Packaging Description
Letrozol CRCA comes in a package containing 90 coated tablets, each with a dosage of 2.5 mg of Letrozole. The packaging is designed to maintain the stability and integrity of the tablets throughout the shelf life.
Clinical Evidence and Proven Effectiveness
Letrozole has been extensively studied in clinical trials for the treatment of hormone receptor-positive breast cancer. Clinical studies have shown that Letrozole is associated with improved disease-free survival and reduced risk of disease recurrence compared to tamoxifen. Additionally, Letrozole has demonstrated a favorable safety profile in postmenopausal women, making it a valuable option in the management of early breast cancer.
